Sertraline updated on 07-01-2025

Atrial septal defect

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7468
R22164		 Anderson, 2020 Atrial septal defect (ASD) – secundum type 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.26 [0.85;1.87] -/-   0/- - -
ref
S7352
R21542		 Wemakor, 2015 Atrial septal defect 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 2.02 [0.71;5.71] 5/19   2,686/19,755 2,691 19
ref
S6018
R15575		 Jimenez-Solem (Controls unexposed, NOS), 2012 Atrial septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) excluded Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.85 [1.35;5.99]
excluded (control group) 		8/817   2,490/843,797 2,498 817
ref
S6023
R15629		 Jimenez-Solem (Controls unexposed, sick), 2012 Atrial septal defects 1st trimester population based cohort retrospective unexposed, sick Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) Unexposed sick: intermediate history of illness/treatment (3-12 months before pregnancy) 1.32 [0.46;3.82] C 8/817   6/806 14 817
ref
S6244
R16516		 Malm, 2011 Atrial septal defects 1st trimester population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: no or not specified 0.93 [0.23;3.76] 2/869   1,279/628,607 1,281 869
ref
Total 4 studies 1.31 [0.93;1.83] 3,986 1,705
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.26[0.85; 1.87]--74%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Wemakor, 2015Wemakor, 2015 2.02[0.71; 5.71]2,6911911%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Jimenez-Solem (Controls unexposed, sick), 2012Jimenez-Solem, 2012 1 1.32[0.46; 3.82]1481710%ROB confusion: criticalROB selection: moderateROB classification: criticalROB missing: lowROB mesure: moderateROB reporting: critical Malm, 2011Malm, 2011 0.93[0.23; 3.76]1,2818696%ROB confusion: criticalROB selection: lowROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (4 studies) I2 = 0% 1.31[0.93; 1.83]3,9861,7050.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, sick;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.16[0.50; 2.70]1,2951,6860%NAJimenez-Solem (Controls unexposed, sick), 2012 Malm, 2011 2 case control studiescase control studies 1.34[0.92; 1.93]2,691190%NAAnderson, 2020 Wemakor, 2015 2 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.31[0.91; 1.86]3,9728880%NAAnderson, 2020 Wemakor, 2015 Malm, 2011 3 unexposed, sickunexposed, sick 1.32[0.46; 3.82]14817 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 Tags Adjustment   - No  - No 1.32[0.46; 3.82]14817 -NAJimenez-Solem (Controls unexposed, sick), 2012 1   - Yes  - Yes 1.31[0.91; 1.86]3,9728880%NAAnderson, 2020 Wemakor, 2015 Malm, 2011 3 Monotherapy   - no or not specified  - no or not specified 0.93[0.23; 3.76]1,281869 -NAMalm, 2011 1   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.34[0.92; 1.93]2,691190%NAAnderson, 2020 Wemakor, 2015 2   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.32[0.46; 3.82]14817 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 Unexposed sick   - intermediate history of illness/tre ...  - intermediate history of illness/treatment (3-12 months before pregnancy) 1.32[0.46; 3.82]14817 -NAJimenez-Solem (Controls unexposed, sick), 2012 1 All studiesAll studies 1.31[0.93; 1.83]3,9861,7050%NAAnderson, 2020 Wemakor, 2015 Jimenez-Solem (Controls unexposed, sick), 2012 Malm, 2011 40.25.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.71.90.8550.000Anderson, 2020Wemakor, 2015Jimenez-Solem (Controls unexposed, sick), 2012Malm, 2011

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 6018

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.62[1.02; 2.57]6,4701,70531%NAAnderson, 2020 Wemakor, 2015 Jimenez-Solem (Controls unexposed, NOS), 2012 Malm, 2011 4 unexposed, sick controlsunexposed, sick controls 1.32[0.46; 3.82]14817 -NAJimenez-Solem (Controls unexposed, sick), 2012 10.510.01.0